Viewing Study NCT01478503


Ignite Creation Date: 2025-12-24 @ 7:32 PM
Ignite Modification Date: 2025-12-30 @ 11:07 PM
Study NCT ID: NCT01478503
Status: COMPLETED
Last Update Posted: 2013-07-02
First Post: 2011-11-21
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: To Evaluate the Blood and Urine Concentration and the Safety and Tolerability of Increasing Repeated Doses of Mirabegron (YM178) OCAS in Healthy Young and Elderly Males and Healthy Young and Elderly Females
Sponsor: Astellas Pharma Inc
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Pharmacokinetics View
None Healthy Subjects View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Pharmacokinetics View
None Mirabegron View
None Phase 1 View
None Dose-Escalation View